Currently, our CE-MS technology is capable of detecting over 80% of all chronic renal diseases including Diabetic Nephropathy (DN).
Focal-segmental Glomerulosclerosis (FSGS)
IgA Nephropathy (IgAN)
Minimal-change Disease (MCD)
Lupus Nephritis (SLE)
Membranous Glomerulonephritis (MGN)
The most prevalent and severe complication of diabetes, the diabetic kidney disease, can be diagnosed much more reliable in a very early stage (3-5 years earlier compared to conventional microalbuminuria test). Furthermore, the method substitutes renal biopsy (puncture of organ) for diagnosis of primary chronic kidney diseases with unsurpassed accuracy and reliability. Analysis of a simple urine sample replaces a two-day hospitalization and avoids biopsy risks such as bleeding, infection or loss of kidney function.
Figure 1: Urinary proteome map focused on the differential diagnosis of renal diseases. For each CE-MS-defined polypeptide of a given pattern with mass plotted against CE migration time (1), the biomarker-defining parameters (mass, CE migration time, protein ID (2), determined polypeptide sequence (4), and fragment information) can be displayed. In addition, the amplitude distribution of the biomarker presuming a Gaussian distribution (3) and statistical data (5) available for selected specific diseases are shown. MS/MS spectrum of the biomarker (6) completes the biomarker information. NC = Normal Control, DN = Diabetic Nephropathy, FSGS = Focal-segmental Glomerulosclerosis, IgAN = IgA Nephropathy, MCD = Minimal-change Disease, SLE = Lupus Nephritis, MGN = Membranous Glomerulonephritis